Securing Pharma reports on a new resolution passed at the WHO to fight the nefarious sale of spurious medicines.
The World Health Organization’s executive board adopted a new resolution on counterfeit and otherwise illegal medicines at its meeting in January, with the aim of establishing a member state ‘mechanism’ to tackle the trade outside of any intellectual property considerations.
The executive board took into account an earlier report by the International Working Group of Member States on Substandard/Spurious/Falsely-Labelled/Falsified/Counterfeit Medical Products (SSFFCs) which concluded that public and health issues – and not IP or trade considerations – should underpin WHO’s activities in this area.
The characteristics of the mechanism remain vague and will no doubt be discussed further when the resolution comes up for debate at the next World Health Assembly in May.
The general principles are that it will make use of existing WHO structures, include expertise in national health and medical products regulatory matters and make recommendations on specific issues, possibly helped by the creation of subsidiary working groups.